AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-2. (Cancelled)
- 3. (Currently amended) A synthetic peptide of about 50 to about 90 amino acids, which comprises
 - (a) a <u>promiscuous</u> helper T cell epitope [[(Th)]],
 - (b) an IgE-CH3 domain antigen peptide, wherein said IgE-CH3 domain antigen peptide i) is between about 25 and about 29 amino acids in length ii) contains two cysteine residues separated by about 23 amino acid residues, and iii) is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:84 and an immunologically functional analog thereof, wherein from one to four of the residues in SEQ ID NO:5 is conservatively substituted or deleted; and optionally
 - (c) an immunostimulatory invasin domain, SEQ ID NO: 13,

wherein the synthetic peptide induces anti-IgE antibody production in a mammal.

- 4-6. (Cancelled)
- 7. (Currently amended) [[A]]<u>The</u> synthetic peptide of claim 3, wherein said <u>helper T cell</u> <u>epitope</u>[[Th]] is an SSAL <u>epitope</u>.
- 8-9. (Cancelled)
- 10. (Previously presented) [[A]]The synthetic peptide of claim 3, wherein said helper T cell epitope[[Th]] has an amino acid sequence selected from the group consisting of SEQ ID NOS: 9-12, SEQ ID NOS: 61-82, and SEQ ID NO: 89.
- 11-28. (Cancelled)